Compare CSPI & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | ALDX |
|---|---|---|
| Founded | 1968 | 2004 |
| Country | United States | United States |
| Employees | 123 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.5M | 101.1M |
| IPO Year | 1994 | 2014 |
| Metric | CSPI | ALDX |
|---|---|---|
| Price | $9.81 | $1.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 9.9K | ★ 891.7K |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | ★ 75.00 | 40.43 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $58,730,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $233.13 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $7.55 | $1.07 |
| 52 Week High | $15.49 | $6.18 |
| Indicator | CSPI | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 57.65 | 36.50 |
| Support Level | $9.72 | $1.48 |
| Resistance Level | $10.59 | $1.88 |
| Average True Range (ATR) | 0.58 | 0.09 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 65.32 | 12.68 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.